Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Haleon Notified GSK and Pfizer that it Rejects their Requests for Indemnification Regarding Zantac

Haleon has notified GSK and Pfizer that it rejects their requests for indemnification on the basis that the scope of the indemnities set out in the joint venture agreement only covers their consumer healthcare businesses as conducted when the JV was formed in 2018. At that time, neither GSK nor Pfizer marketed OTC Zantac in the US or Canada.
byCharles Gross
September 20, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

Haleon has notified GSK and Pfizer that it rejects their requests for indemnification on the basis that the scope of the indemnities set out in the joint venture agreement only covers their consumer healthcare businesses as conducted when the JV was formed in 2018. At that time, neither GSK nor Pfizer marketed OTC Zantac in the US or Canada.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Simon Property Group Reports Better-Than-Expected Q4 Results, Raises Quarterly Dividend

By Erica Kollmann
February 5, 5:45 PM
Simon Property Group reported quarterly FFO of $3.69 per share which beat the analyst consensus estimate of $3.34 by 10.48%. The company reported quarterly sales of $1.53 billion which beat the analyst consensus estimate of $1.36 billion by 12.38% and represents a 9.07% increase over sales of $1.4 billion from the same period last year.

SPG